<DOC>
	<DOCNO>NCT00309907</DOCNO>
	<brief_summary>This phase II trial study well etanercept work treat young patient idiopathic pneumonia syndrome undergo donor stem cell transplant . Etanercept may effective treat patient idiopathic pneumonia syndrome undergo donor stem cell transplant .</brief_summary>
	<brief_title>Etanercept Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing Donor Stem Cell Transplant</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate , define survival complete discontinuation supplemental oxygen day 28 , pediatric patient acute noninfectious pulmonary dysfunction ( idiopathic pneumonia syndrome [ IPS ] ) undergo allogeneic stem cell transplantation treat etanercept . SECONDARY OBJECTIVES : I . Estimate day 56 survival rate patient treat drug . II . Determine overall survival distribution patient treat drug . III . Determine pulmonary response , define time discontinuation supplemental oxygen , patient treat drug . IV . Evaluate toxicity etanercept therapy patient IPS . V. Evaluate level pro-inflammatory cytokine , bronchoalveolar lavage ( BAL ) fluid serum , patient IPS . VI . Describe C-reactive protein ( CRP ) level baseline , day 7 , 14 , 21 , 28 association response patient IPS . OUTLINE : This open-label , nonrandomized , multicenter study . Patients receive etanercept IV 30 minute day 0 subcutaneously day 3 , 7 , 10 , 14 , 17 , 21 , 24 . Treatment continue absence infectious pathogen , disease progression , unacceptable toxicity . Patients also receive methylprednisolone ( corticosteroid equivalent ) IV day 0-2 orally taper day 56 . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Rhabdomyosarcoma</mesh_term>
	<mesh_term>Wilms Tumor</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Rhabdomyosarcoma , Embryonal</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Diagnosis acute , noninfectious idiopathic pulmonary dysfunction ( IPS ) define follow : Evidence diffuse lung injury occur within first several month hematopoietic stem cell transplantation infectious etiology identify . To meet criterion IPS must : Evidence widespread alveolar injury Diffuse multilobar infiltrate chest xray CT scan Evidence abnormal respiratory physiology base upon 1 follow : Room air oxygen saturation &lt; 93 % Supplemental oxygen require maintain oxygen saturation ≥ 93 % Absence active low respiratory tract infection , define Bronchoalveolar lavage ( BAL ) negative infection base one following : Gram stain , fungal stain , acidfast bacillus stain Bacterial culture ( quantitative culture ≥ 10^4 colonyforming units/mL consider positive ) Fungal culture Mycobacterial culture Viral culture ( respiratory syncytial virus [ RSV ] , parainfluenza , adenovirus , influenza A B , cytomegalovirus [ CMV ] ) If direct fluorescent antibody ( DFA ) screen perform BAL , must negative virus list Pneumocystis carinii pneumonia polymerase chain reaction ( PCR ) , DFA stain , cytology Evidence bilateral pulmonary infiltrates ( chest radiograph ) Patients may diffuse alveolar hemorrhage ( DAH ) periengraftment respiratory distress syndrome ( PERDS ) Presence `` mixed oral flora , '' `` rare Candida specie , '' presence Penicillium specie report BAL fluid analysis allow A radiographic find pulmonary edema exclude diagnosis IPS , provide criterion meet provided treating physician conclude clinical ( echocardiographic ) criterion pulmonary edema secondary cardiac dysfunction iatrogenic fluid overload Patients must require supplemental oxygen Must undergone allogeneic bone marrow , cord blood , peripheral blood stem cell transplantation within past 120 day There restriction base upon underlying disease , donor source , degree HLA match , intensity pretransplant condition regimen , use prior donor leukocyte infusion Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No document invasive fungal systemic viral infection within past 14 day Patients asymptomatic viruria allow No sign CMV reactivation ( CMV , PCR , antigenemia , shell vial culture ) within past 14 day No sepsis syndrome hypotension require inotropic support ( except dopamine &lt; 5mcg/kg/minute ) No documented bacteremia within past 48 hour Persistent fever allow No evidence cardiac failure clinical echocardiographic finding No know hypersensitivity etanercept No known history tuberculosis ( Tb ) prior Tb exposure No prior chronic hepatitis B hepatitis C infection Concurrent treatment acute chronic GVHD allow More 14 day since prior etanercept More 7 day since prior investigational drug trial ( phase I , II , III ) treatment acute graftversushost disease ( GVHD ) Not mechanical ventilation &gt; 48 continuous hour prior study entry Must receive &gt; 2 mg/kg/day methylprednisolone corticosteroid equivalent within 24 hour study entry Concurrent continuous venovenous hemofiltration hemodialysis allow</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>